Return to flip book view

TMLorem ipsumGala

Dear Friends,Welcome to The Glaucoma Foundation’s 41st anniversary gala. Tonight we celebrate the accomplishments of four people whose dedication to research, education, and patient care has been instrumental in advancing our mission to find a cure and improve life for millions of people living with glaucoma. Congratulations to David Fellows, Helga Tan-Fellows, Kumar Mahadeva, and Simi Ahuja. We are honored to recognize your lifetime achievements and exceptional generosity.Here’s to a wonderful evening and a bright future!Gregory K. Harmon, MDChairman of the BoardLouis E. Pasquale, MD, FARVO Elena Sturman Chairman, Scientific Advisory Board President and CEO

PROGRAMWelcome by Elena Sturman, President and CEOMaster of Ceremonies, Jai G. Parekh, MD, MBAOpening VideosDinnerJahkori Dopwell-HallTribute to Kitty Carlisle HartTHE KITTY CARLISLE HART AWARD OF MERIT FOR LIFETIME ACHIEVEMENTDavid Fellows and Helga Tan-FellowsAward Presented by Hillary GoldenKumar Mahedva and Simi AhujaAward Presented by Adriana Di Polo, PhDClosing RemarksElena SturmanGala

The Glaucoma Foundation (TGF) is one of the leading not-for-profits in the world dedicated to the study of glaucoma and the search for its cure. Attracting scientists from other specialties in ophthalmology and in all areas of biosciences, nanotechnology, and AI into glaucoma research, the Foundation has significantly expanded the number of people working in the field and continues to bring new insights and approaches to understanding and treatment. Through the generous contributions of individuals, institutions, corporations, and foundations, TGF identifies and promotes substantive research and provides information, education, and support for glaucoma patients and caregivers.

Gregory K. Harmon, MDChairman of the Board-TGFAssociate Professor of OphthalmologyWeill Medical College of Cornell UniversityNew York Presbyterian HospitalLouis Pasquale, MD, FARVOChairman of Scientific Advisory Board-TGFSite Chair, Department of OphthalmologyMount Sinai HospitalVice Chair, Translational Ophthalmology Research Shelley and Steven Einhorn Distinguished ProfessorMount Sinai Healthcare SystemJohn Berdahl, MDOphthalmologist, Vance Thompson VisionBarbara CalabaStrategic Brand Planner, AdvertisingCarole Darden-LloydSocial Worker and Child Therapist (Ret.)Reza Dibadj, MBA, JDProfessor of Law, University of San FranciscoManaging Partner, Park & Dibadj, LLP David FellowsChairman of the Board, Beacon TherapeuticsMurray Fingeret, ODClinical Professor, SUNY College of OptometryBarry S. FriedbergCo-Chairman of the Board New York Private Bank & Trust Company.Annette Oestreicher GrollmanPresident, Oestreicher Medical Communications (Ret.)Alon Harris, MS, PhD, FARVO Vice Chair of International Research and Academic Affairs Director of Ophthalmic Vascular Diagnostic & Research ProgramProfessor of Ophthalmology,Icahn School of Medicine, Mount Sinai Barbara HearstArtistMitch HillBusiness Advisor, Inari Medical, Inc. Patricia HillPsychotherapistJeffrey M. Liebmann, MDShirlee and Bernard Brown Professor of OphthalmologyVice Chair, Department of OphthalmologyDirector, Glaucoma DivisionEdward S. Harkness Eye InstituteColumbia University Medical CenterKumar MahadevaFounder and Former CE0Cognizant Technology SolutionsKenneth MortensonFormer Managing Dir.Oppenheimer Capital (Ret.) Jai G. Parekh, MD, MBA, FAAOClinical Associate Professor of OphthalmologyThe New York Eye & Ear Infirmary of Mount SinaiThe Icahn School of Medicine, NYCo-Founder, EyeCare Consultants of NJ Joe RosenManaging PartnerPlasma Consultants, LLCBaldo Scassellati Sforzolini, MDGlobal Head of R&DGaldermaSheldon M. SiegelFormer CFO and Managing DirectorOppenheimer Capital (Ret.)PRESIDENT & CHIEF EXECUTIVE OFFICERElena SturmanBOARD OF DIRECTORS

PROUD TO SERVE TGF,TO CELEBRATE THE FOUNDATION’S REMARKABLE ACHIEVEMENTS,AND TO HONOR THE RECIPIENTSOF TONIGHT’S PRETIGIOUS AWARDS.Jay HoffmanGregory K. Harmon, MD41ST ANNIVERSARY CO-CHAIRS

MASTER OF CEREMONIESJAI PAREKH, MD, MBADr. Jai Parekh, known as “DrJ,” is a board-certified anterior segment ophthalmic surgeon in the NJ/NY area. He is Co-Founder and CEO of the renamed EyeCare Consultants of NJ, a 50-year old comprehensive ophthalmology practice in NJ. He is also Chief of Cornea & Medical Director of the Research Institute at St. Joseph’s HealthCare System in NJ. Dr. Parekh is an active Clinical Associate Professor of Ophthalmology on the Cornea Service at the New York Eye & Ear Infirmary of Mt. Sinai & Icahn School of Medicine where he did his fellowship over 24 years ago. He completed medical school at the Boston University School of Medicine Early Acceptance Integrated Program and remained in Boston to fully train in Internal Medicine and Ophthalmology where he was Chief Resident in both specialties. DrJ co-founded and was chosen to be on the Board of Directors for the Society of Academic Medicine, the Vanguard Ophthalmic Society, the American-European College of Ophthalmic Surgery (AECOS), & CEDARS-ASPEN Society. He is currently on the Editorial Board for the Technology Section of Ocular Surgery News and has also served on the Editorial Board of Cataract & Refractive Surgery Today. DrJ is an active board member for The Glaucoma Foundation, The Lighthouse Guild, and Ophthalmic World Leaders as well as on many scientific advisory boards. DrJ is Chief Innovation Ocer for EyeCheq, a Miami-based AI/Digital HealthCare Co & was also recently Chief Medical Ocer for EyeCare at Allergan between 2015-2020 before their recent acquisition by Abbvie. DrJ’s interests include ocular surface & external diseases, cataract surgery and innovation, minimal invasive glaucoma surgery, practice/disease management, digital healthcare, entrepreneurship, and medical philanthropy; he earned an MBA with a concentration in HealthCare Management at the Fuqua School of Business at Duke University nearly 15 years ago while still in active practice. He resides in NJ with his wife of 30 years, his 3 children, and two dogs. They are ocially empty-nesters!

41ST ANNIVERSARY CO-CHAIRS JAY HOFFMANJay Homan founded Gallery Systems, a software firm that supports over a thousand museums globally, and acted as its CEO for many years. The company was acquired by a Toronto-based public company in 2012. Homan now serves as a portfolio manager and works in mergers and acquisitions. Prior to founding Gallery Systems, Homan worked in real estate development for a New York-based insurance holding company. In addition to his M&A work, Homan serves on the director’s advisory council of a university museum and the board of a private Toronto-based corporation specializing in fundraising software for nonprofit organizations. Homan lives in New York with his husband and their two children.Gala

41ST ANNIVERSARY CO-CHAIRS GREGORY K. HARMON, MDDr. Greg Harmon has been the chairman of The Glaucoma Foundation since 1999 and member of the board since 1993. In addition to his private practice in Manhattan, specializing in glaucoma and cataract surgery, he holds voluntary faculty positions as clinical associate professor of ophthalmology at Weill Medical College of Cornell University/New York Presbyterian Hospital and associate adjunct surgeon at The New York Eye and Ear Infirmary. He serves on the medical sta at Manhattan Eye Ear & Throat Hospital (MEETH).Dr. Harmon is a graduate of Johns Hopkins University and Mount Sinai School of Medicine. He completed his internship in internal medicine at St. Luke’s Roosevelt Hospital and his residency in ophthalmology and fellowship in glaucoma at Cornell Medical Center. He is a board certified diplomate of the American Board of Ophthalmology and a member of the board of the World Glaucoma Patient Association.Dr. Harmon has long been an advocate for public education about glaucoma and for widespread glaucoma screening. He has produced and been featured in news segments and public service announcements that have achieved national media distribution. One with the late actress Kitty Carlisle Hart resulted in thousands of Americans receiving free literature about the disease. He has conducted glaucoma screenings at large corporations and among high-profile organizations such as the New York Yankees and Mets. He has written patient educational guides, contributed to textbooks, and published in peer-reviewed medical journals. He is the author of “What Your Doctor May Not Tell You about Glaucoma – The Essential Treatments and Advances That Could Save Your Sight” (Warner Books, 2004).

TMLorem ipsumThe Carlisle Hart Award is given to accomplished people who are living with eye disease, and the people and organizations who champion them. Erik Weihenmayer, Kirby Puckett, Aaryn Landers Lamb, President George H.W. Bush, Cecil M. Payne, EBONY magazine, Tom Sullivan, Ronnie Milsap, Christopher Gardner, Governor David Patterson, John Patrick Shanley, Elliot Erwitt, Joseph Lovett, Steve Tyrell, STRONG-CUEVAS (Elizabeth de Cuevas), Dr. Bruce Spivey, H.E. Ambassador Francis M. Deng, Joseph M. La Motta, Ron Chernow, Kenneth Mortenson, Linda Mortenson, Barry Friedberg, and Charlotte Moss have received the award at previous TGF galas.The Glaucoma Foundation is honored to present this year’s Kitty Carlisle Hart Award of Merit for Lifetime Achievement to TGF Board members David Fellows and Kumar Mahade-va, and their spouses Helga Tan-Fellows and Simi Ahuja, for excellence and integrity in their chosen professions, excep-tional philanthropy, and dedication to our mission to improve the lives of glaucoma patients around the world.

2025“I was having my eyes examined and the doctor thought my eye pressure seemed a little high. He brought me to see Dr. Harmon, who told me that I had glaucoma. I didn’t know it. I had no symptoms. I could have lost my sight. It could have been stolen away without the slightest indication it was on its way out.”Kitty Carlisle Hartfrom her forward to Dr. Gregory Harmon’s book, “What Your Doctor May Not Tell You About Glaucoma.”GalaTHE KITTY CARLISLE HART AWARD OF MERIT FOR LIFETIME ACHIEVEMENT

41st Anniversary

41 st AnniversaryWe are deeply honored to receive the Kitty Carlisle Hart Award. This moment allows us to celebrate The Glaucoma Foundation and, more importantly, to join all of you in embracing the powerful opportunities that lie ahead. Together, let’s create meaningful change and make a lasting impact. Kumar MahadevaSimi Ahuja

THE KITTY CARLISLE HARTAWARD OF MERITFOR LIFETIME ACHIEVEMENTKUMAR MAHAEDASIMI AHUJA

Kumar Mahadeva is the Founder and former Chairman and CEO of Cognizant Technology Solutions, a $42 billion NASDAQ 100 company he established in 1993. With a distinguished career, he has held senior executive roles at McKinsey & Company, AT&T, and Dun & Bradstreet, and founded the private equity firm Kubera Partners. Currently, Mr. Mahadeva leads his family oce and foundation while also serving on the boards of several private technology companies in which he is invested. His commitment to philanthropy extends to multiple nonprofit boards, as well as the Harvard Business School International Advisory Board. Mr. Mahadeva holds a Master’s in Electrical Engineering from Cambridge University (UK) and an MBA from Harvard Business School. He has a personal interest in Glaucoma, as he is a patient himself.Simi Ahuja is an avid contemporary art collector with a strong focus on supporting underrepresented voices from the Global South. As a trustee for the Bass Museum of Art and a member of the Collectors Council at the Pérez Art Museum, Simi plays an integral role in advancing the missions of several Miami-based arts organizations. A passionate advocate for women artists, Simi is committed to creating platforms that celebrate their work and foster greater visibility within the global art community.THE KITTY CARLISLE HART AWARD OF MERIT FOR LIFETIME ACHIEVEMENT

41 st Anniversary

41 st AnniversaryEvery anniversary is an opportunity to renew our dedication, reignite our passion, and continue creating a lasting legacy.we are honored to receivethe kitty carlisle hart awardand to support the work of TGF.David FellowsHelga Tan-Fellows

THE KITTY CARLISLE HARTAWARD OF MERITFOR LIFETIME ACHIEVEMENTDAVID FELLOWSHELGA TAN FELLOWS

David Fellows has 45 years of experience in various leadership roles within the biopharmaceutical industry and currently is the Board Chairman at Beacon Therapeutics and Terns Pharmaceuticals.He was previously CEO of Nightstar Therapeutics, a company specializing in developing drugs for inherited retinal diseases, which he led through a successful NASDAQ listing and M&A transaction. Prior to that, he was a Vice President at Johnson & Johnson’s Vision Care franchise and spent 25 years at Allergan (Abbvie) where he was Regional President of Europe/Asia. Mr. Fellows holds a degree in Psychology from Butler University.Helga Tan-Fellows studied industrial engineering with a master in business administration and a minor in information technology. She spent more than 20 years in the manufacturing of both ophthalmic and medical device products. Since its founding in 2104, Helga has been the CFO (Chief Farming Ocer) of Gyo Greens, a hydroponic and aquaculture farm in Ponte Vedra Beach, FL with a mission focused on education and sustain-able farming. Dave and Helga currently split their time between Ponte Vedra Beach and London, UK. THE KITTY CARLISLE HART AWARD OF MERIT FOR LIFETIME ACHIEVEMENT

TO TONIGHT’S HONOREESWe are thrilled to jointhe Foundation in celebratingyour exceptional accomplishments,vision and generosity.Here’s to even bettervision in the years ahead.Mitch and Julie Hill

Congratulationsto The Glaucoma Foundationand the 41st Anniversary Honorees.We are grateful for all of your work, research, and education to help those with glaucoma.We look forward to your continued innovative research in nding a cure for glaucoma. Mortenson Family

“Vision is the art of seeing what is invisible to others” Jonathan Swift Congratulations Dave and Helga! Thank you for your time, expertise, and vision that brings light to improve the lives of patients with glaucoma. Scott and Joy Whitcup

TO TGF AND TONIGHT’S HONOREESWe look forward to many more years of success and innovation.Cindy Liebmann Jeffrey Liebmann, M D

Happy 41st anniversary, TGF.Over the decades, we have achieved remarkable milestones and created an enduring foundation for the future.Congratulations and appreciation for our wonderful honorees.Proud of all the fellows!Patricia Hill

Thank you to David & Helga Fellows and Kumar & Simi Mahadeva for your continued passion and dedication to glaucoma research. Your leadership is inspiring!Carole Darden Lloyd Edward Lloyd

To the honorees,for their steadfast dedicationto The Glaucoma Foundation.Thank you for your commitmentthat has impacted the lives of many. Marilyn and Joe Rosen

Not an actual patient.BRIDGE THE GAPFOR REFRACTORY GLAUCOMAWITH MINIMALLY INVASIVE FILTERING SURGERY CONSIDER XEN® FOR THE NEXT STOP ON YOUR PATIENT’S TREATMENT JOURNEY. XEN® Gel Stent is a proven pathway to IOP control for refractory glaucoma patients.1 • From a wide range of baseline pressures,* XEN® Gel Stent achieved a mean IOP of15.9 (± 5.2) mm Hg through 12 months (n = 52)1, 2 • 76% of XEN® Gel Stent patients achieved a ≥ 20% IOP reduction in the ITT group(N = 65)1• 81% of XEN® Gel Stent patients achieved a ≥ 25% IOP reduction among thosecompleting the 12-month visit (n = 52)2• Pivotal safety data included 0% intraoperative complications (0/65) and 0%persistent hypotony (0/65); transient hypotony† occurred in 24.6% of patients (16/65)1IOP = intraocular pressure; ITT = intent to treat. * In the XEN® Gel Stent clinical study, baseline medicated IOP ranged from 20.0 to 33.7 mm Hg.2 † No clinically significant consequences were associated with hypotony, such as choroidal effusions, suprachoroidal hemorrhage, or hypotony maculopathy. IOP < 6 mm Hg was defined as an adverse event, regardless of whether there were any associated complications or sequelae related to the low pressure. Thirteen cases occurred at the 1-day visit; there were no cases of persistent hypotony, and no surgical intervention was required for any case of hypotony.1INDICATIONS The XEN® Glaucoma Treatment System (XEN® 45 Gel Stent preloaded into a XEN® Injector) is indicated for the management of refractory glaucomas, including cases where previous surgical treatment has failed, cases of primary open-angle glaucoma, and pseudoexfoliative or pigmentary glaucoma with open angles that are unresponsive to maximum tolerated medical therapy.IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS XEN® Gel Stent is contraindicated in angle-closure glaucoma where angle has not been surgically opened, previous glaucoma shunt/valve or conjunctival scarring/pathologies in the target quadrant, active inflammation, active iris neovascularization, anterior chamber intraocular lens, intraocular silicone oil, and vitreous in the anterior chamber.WARNINGS XEN® Gel Stent complications may include choroidal effusion, hyphema, hypotony, implant migration, implant exposure, wound leak, need for secondary surgical intervention, and intraocular surgery complications. Safety and effectiveness in neovascular, congenital, and infantile glaucoma has not been established. Avoid digital pressure following implantation of the XEN® Gel Stent to avoid the potential for implant damage.PRECAUTIONS Examine the XEN® Gel Stent and XEN® Injector in the operating room prior to use. Monitor intraocular pressure (IOP) postoperatively and if not adequately maintained, manage appropriately. Stop the procedure immediately if increased resistance is observed during implantation and use a new XEN® system. Safety and effectiveness of more than a single implanted XEN® Gel Stent has not been studied.ADVERSE EVENTS The most common postoperative adverse events included best- corrected visual acuity loss of ≥ 2 lines (≤ 30 days 15.4%; > 30 days 10.8%; 12 months 6.2%), hypotony IOP < 6 mm Hg at any time (24.6%; no clinically significant consequences were associated, no cases of persistent hypotony, and no surgical intervention was required), IOP increase ≥ 10 mm Hg from baseline (21.5%), and needling procedure (32.3%). Caution: Federal law restricts this device to sale by or on the order of a licensed physician. For the full Directions for Use, please visit www.allergan.com/xen/usa.htm or call 1-800-678-1605. Please call 1-800-433-8871 to report anadverse event.Please see full Directions for Use at https://www.rxabbvie .com/pdf/xen_dfu.pdf© 2024 AbbVie. All rights reserved. All trademarks are the property of their respective owners.US-XEN-240031 04/2024 025426References: 1. XEN® Directions for Use. 2. Grover DS, Flynn WJ, Bashford KP, et al. Performance and safety of a new ab interno gelatin stent in refractory glaucoma at 12 months. Am J Ophthalmol. 2017;183:25-36. doi:10.1016/j.ajo.2017.07.023.SHATTERING THESTATUS QUOINTERVENTIONAL GLAUCOMAiDose TR is a long duration intracameral procedural pharmaceutical that delivers prostaglandin analog therapy for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.1The catalyst to advance the interventional glaucoma revolution, helping you and your patients take back control of their treatment journey. Actual size 1.8mm x 0.5mm ©2024 Glaukos Corporation.All rights reserved. iDose TR and Glaukos are registered trademarks of Glaukos Corporation. PM-US-1761INDICATIONS AND USAGEiDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).IMPORTANT SAFETY INFORMATIONDOSAGE AND ADMINISTRATIONFor ophthalmic intracameral administration.The intracameral administration should be carried out under standard aseptic conditions.CONTRAINDICATIONSiDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch’s Dystrophy,corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet’s Stripping Automated Endothelial Keratoplasty [DSAEK]),patients with hypersensitivity to travoprost or to any other components of the product.WARNINGS AND PRECAUTIONSiDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to conrm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent.ADVERSE REACTIONSIn controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual eld defects,eye pain, ocular hyperaemia, and reduced visual acuity.Please see full Prescribing Information. You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.You may also call Glaukos at 1-888-404-1644.1. iDose TR (travoprost intracameral implant) 75 mcg Prescribing Information. Glaukos Corporation. 2023.View full prescribing information at iDoseTRhcp.com

SHATTERING THE STATUS QUOINTERVENTIONAL GLAUCOMAiDose TR is a long duration intracameral procedural pharmaceutical that delivers prostaglandin analog therapy for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.1The catalyst to advance the interventional glaucoma revolution, helping you and your patients take back control of their treatment journey. Actual size 1.8mm x 0.5mm ©2024 Glaukos Corporation. All rights reserved. iDose TR and Glaukos are registered trademarks of Glaukos Corporation. PM-US-1761INDICATIONS AND USAGEiDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).IMPORTANT SAFETY INFORMATIONDOSAGE AND ADMINISTRATIONFor ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions.CONTRAINDICATIONSiDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch’s Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet’s Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product.WARNINGS AND PRECAUTIONSiDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to conrm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent.ADVERSE REACTIONSIn controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual eld defects, eye pain, ocular hyperaemia, and reduced visual acuity.Please see full Prescribing Information. You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also call Glaukos at 1-888-404-1644.1. iDose TR (travoprost intracameral implant) 75 mcg Prescribing Information. Glaukos Corporation. 2023.View full prescribing information at iDoseTRhcp.com

New World Medical’s mission is to preserve and enhance vision by delivering innovations to ben-efit humanity. With a strong fo-cus on surgical glaucoma, our innovative portfolio includes the Ahmed® Glaucoma Valve (AGV), Ahmed ClearPath®, KDB GLIDE®, STREAMLINE® Surgical System and VIA360™ Surgical System. With an unwavering commitment to quality and global access, we develop products that provide long-lasting, often life-changing benefits to a person’s eyesight and well-being.The Ahmed® Glaucoma Valve is designed for patients with severe glaucoma. As a leader in glauco-ma drainage for over 30 years, the AGV is more than an implant — it’s a proven solution. Its unique features include a nonobstruc-tive valve system that eectively reduces and controls intraocular pressure. The Ahmed ClearPath® 250 and 350 are valveless drain-age devices that oer flexibili-ty and a natural fit for patients, giving ophthalmologists options based on patient needs.For patients with early-stage glau-coma, the KDB GLIDE® provides precision in excising diseased trabecular meshwork for Primary Open Angle Glaucoma, making it ideal for both standalone and combined cataract surgeries. The STREAMLINE® Surgical Sys-tem is a first-line, implant-free solution developed in collabo-ration with ophthalmologists. It allows precise viscoelastic injec-tions during standalone and com-bined cataract surgeries, empow-ering surgeons to leave only their best work behind. The VIA360™ Surgical System oers single entry, on demand viscoelastic delivery with intui-tive features that enhance both control and comfort, improving the overall surgical experience. VIA360 can be used in combina-tion with cataract surgery or as a standalone procedure, ultimately oering flexibility to the surgical workflow.In addition to our commitment to innovation, we uphold a strong dedication to philanthropy. Through the Sidra Tree Foun-dation, we work to democratize eye care globally by investing in healthcare systems in developing nations. Our investments ensure our mission to improve vision ex-tends beyond product innovation to make a lasting impact on com-munities worldwide. NEW WORLD MEDICALLearn more about our mission and innovative solutions at www.newworldmedical.com

ZEISS Glaucoma Work owDetecting disease early and managing progression reliably.Assess & educateZEISS CLARUS 500: The  rst fundus imaging system to provide true color and clarity within an ultra-wide  eld of view, enabling clinicians to capture high-resolution fundus images from macula to the far periphery.ZEISS SL 800 with ZEISS SL Imaging Solution: ZEISS takes your everyday slit lamp exams to the next level by adding the integration of high-quality image and video capture to exam reports, off ering you the ability to document cases, including patient education, teaching or publishing.Plan ZEISS CIRRUS 6000: The next-generation OCT from ZEISS, delivering high-speed image capture with high-de nition imaging detail and a wide  eld of view.ZEISS HFA3 Perimeter: The gold standard of perimetry, with SITA Faster expanded testing options and reduced patient test times.Treat ZEISS ARTEVO 850: Surgical microscopes from ZEISS for excellence in optics, illumination and ergonomics. ZEISS CALLISTO eye markerless technology available. ZEISS VISULAS combi: First fully integrated therapeutic laser workstation off ering photodisruption and photocoagulation technology without compromise. CheckZEISS Glaucoma Workplace: Analyze side-by-side progression data from ZEISS CIRRUS OCT and ZEISS HFA at a glance. The Progression Summary display intelligently con gures the Structure-Function Guided Progression Analysis (GPA™) to show speci cally where change (OCT) or progression (perimetry) has been detected. * The link directs to an International website. This site features our entire product portfolio worldwide. The products featured may not be available in the US. Please contact your local representative for more information.CAP-en-US_31_035_0078II © Carl Zeiss Meditec, Inc., 2025. All rights reserved.Not all products, services, or off ers are approved or off ered in every market and approved labeling and instructions may vary from one country to another. For country-speci c productinformation, see the appropriate country website. Product speci cations are subject to change in design and scope of delivery as a result of ongoing technical development.Contact your ZEISS representative to discuss how ZEISS Glaucoma Work ow can help you streamline your practice and provide a better patient experience. And for more about our products and solutions visit: zeiss.com/glaucomawork ow.*PART OF THE ZEISS MEDICAL ECOSYSTEM Assess & educateTreatPlan Check

ZEISS Glaucoma Work owDetecting disease early and managing progression reliably.Assess & educateZEISS CLARUS 500: The  rst fundus imaging system to provide true color and clarity within an ultra-wide  eld of view, enabling clinicians to capture high-resolution fundus images from macula to the far periphery.ZEISS SL 800 with ZEISS SL Imaging Solution: ZEISS takes your everyday slit lamp exams to the next level by adding the integration of high-quality image and video capture to exam reports, off ering you the ability to document cases, including patient education, teaching or publishing.Plan ZEISS CIRRUS 6000: The next-generation OCT from ZEISS, delivering high-speed image capture with high-de nition imaging detail and a wide  eld of view.ZEISS HFA3 Perimeter: The gold standard of perimetry, with SITA Faster expanded testing options and reduced patient test times.Treat ZEISS ARTEVO 850: Surgical microscopes from ZEISS for excellence in optics, illumination and ergonomics. ZEISS CALLISTO eye markerless technology available. ZEISS VISULAS combi: First fully integrated therapeutic laser workstation off ering photodisruption and photocoagulation technology without compromise. CheckZEISS Glaucoma Workplace: Analyze side-by-side progression data from ZEISS CIRRUS OCT and ZEISS HFA at a glance. The Progression Summary display intelligently con gures the Structure-Function Guided Progression Analysis (GPA™) to show speci cally where change (OCT) or progression (perimetry) has been detected. * The link directs to an International website. This site features our entire product portfolio worldwide. The products featured may not be available in the US. Please contact your local representative for more information.CAP-en-US_31_035_0078II © Carl Zeiss Meditec, Inc., 2025. All rights reserved.Not all products, services, or off ers are approved or off ered in every market and approved labeling and instructions may vary from one country to another. For country-speci c product information, see the appropriate country website. Product speci cations are subject to change in design and scope of delivery as a result of ongoing technical development.Contact your ZEISS representative to discuss how ZEISS Glaucoma Work ow can help you streamline your practice and provide a better patient experience. And for more about our products and solutions visit: zeiss.com/glaucomawork ow.*PART OF THE ZEISS MEDICAL ECOSYSTEM Assess & educateTreatPlan Check

Pioneering the future of retina clinical researchEvery day, our global teams proudly push the boundaries of clinical trial innovation to guide cutting-edge therapies to market.See more at oraclinical.com© 2025 Sight Sciences. Sight Sciences and the Sight Sciences logo are registered tardemarks of Sight Sciences. 03/2025 SS-3167-US.v2Sight Sciencesis a proud sponsor of The Glaucoma Foundation.We congratulate all the honorees and celebrate The Glaucoma Foundation’s 41st anniversary! At Sight Sciences, we share a similar vision. We have embarked on a mission to develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care – empowering people to keep seeing.

Howe-Lewis Internationalis pleased to supportThe Glaucoma Foundation 41st Anniversary Galaand applauds the2025 Kitty Carlisle Hart Award of Merit for Lifetime Achievement HonoreesHowe-Lewis InternationalExecutive search specialists to the not-for-prot communityPatty Greco and Esther RosenbergCo-Managing Directorshowe-lewis.comCONGRATULATIONSDAVID, HELGA, KUMAR, AND SIMI!The staff of TGFAndrea, Angela, and ClyTM

David, Kumar, Simi, Helga,Thank you for your friendship, your generosity, and your vision for the future!Elena Sturman

Helga and Dave. Thank you for your many contributions to glaucoma research.Congratulations!Suki and L Kaplan. Yuko and Brad Hu

In honor ofDavid Fellows, Helga Tan-Fellows,Kumar Mahadeva, and Simi AhujaWe celebrate your achievementsand the enduring mission ofThe Glaucoma Foundation.Barry FriedbergCharloe Moss

2025 Gala SponsorsPLATINUMDavid Fellows and Helga Tan-FellowsKumar Mahadeva and Simi AhujaRUBYGregory K. Harmon, MDAMETHYSTBarry Friedberg and Charlotte MossJeffrey M. Liebmann, MDMortenson FamilyJoe and Marilyn Rosen EMERALDPatricia HillThéa PharmaSAPPHIREAbbVieBausch + LombExSight VenturesCarole Darden-Lloyd and Edward G. LloydNew York Eye and Ear Inrmary of Mount SinaiRajen SavjaniSight SciencesCRYSTALGlaukosMitch HillNew World MedicalOra ClinicalZEISS

TMLorem ipsumwww.glaucomafoundaon.org